170 results on '"Kirstein, Mark N"'
Search Results
2. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
3. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning
4. A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation
5. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis
6. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion
7. Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis
8. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)
9. Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer.
10. Predictive Value of C‐Reactive Protein and Albumin for Temporal Within‐Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation
11. Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis.
12. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation
13. Cap-dependent translation blockade and fixed dose-rate gemcitabine: Interaction in an in vitro bioreactor system
14. CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant
15. Population Pharmacokinetic Analysis of Phosphoramide Mustard Following Cyclophosphamide Administration in Hematopoietic Cell Transplant Conditioning Therapy
16. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors
17. Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine
18. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid
19. Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C
20. Enhanced Sensitivity Method for Measuring Gemcitabine in Human Plasma
21. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system
22. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens
23. Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system
24. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC
25. Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo
26. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients
27. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors
28. Review of Selected Patents for Cancer Therapy Targeting: Tumor Angiogenesis
29. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction
30. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
31. A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation
32. Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines
33. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
34. Erratum: Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)
35. Fusion of kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
36. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection
37. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion
38. New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065
39. Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma
40. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery and intravenous infusion.
41. Final results of a phase 1 trial of sorafenib, pemetrexed, and cisplatin in patients with advanced solid tumors.
42. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning
43. Pharmacokinetic–pharmacodynamic modelling of acute N‐terminal pro B‐type natriuretic peptide after doxorubicin infusion in breast cancer
44. A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms.
45. Abstract B65: Immune cell priming and potentiation of anti-tumor effects by Imprime PGG®
46. Abstract 1882: Gemcitabine pathway SNPs are associated with its PK parameters in patients with solid tumors
47. Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors
48. Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine
49. Combinatorial Pharmacologic Effects of Gemcitabine and its Metabolite dFdU
50. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.